MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-024-47057-2

Медицинская библиотека · Nature communications · 2024

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Keller Michael D, Hanley Patrick J, Chi Yueh-Yun, Aguayo-Hiraldo Paibel, Dvorak Christopher C, Verneris Michael R, Kohn Donald B, Pai Sung-Yun, Dávila Saldaña Blachy J, Hanisch Benjamin, Quigg Troy C, Adams Roberta H, Dahlberg Ann, Chandrakasan Shanmuganathan, Hasan Hasibul, Malvar Jemily, Jensen-Wachspress Mariah A, Lazarski Christopher A, Sani Gelina, Idso John M, Lang Haili, Chansky Pamela, McCann Chase D, Tanna Jay, Abraham Allistair A, Webb Jennifer L, Shibli Abeer, Keating Amy K, Satwani Prakash, Muranski Pawel, Hall Erin, Eckrich Michael J, Shereck Evan, Miller Holly, Mamcarz Ewelina, Agarwal Rajni, De Oliveira Satiro N, Vander Lugt Mark T, Ebens Christen L, Aquino Victor M, Bednarski Jeffrey J, Chu Julia, Parikh Suhag, Whangbo Jennifer, Lionakis Michail, Zambidis Elias T, Gourdine Elizabeth, Bollard Catherine M, Pulsipher Michael A

Многоцентровое исследованиеКлиническое исследование II фазыСтатьяПеревод в очереди

Аннотация

Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter study (NCT03475212) for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus. Primary endpoints were feasibility, safety, and clinical responses (>1 log reduction in viremia at 28 days). Secondary endpoints were reconstitution of antiviral immunity and persistence of the infused VSTs. Suitable VST products were identified for 75 of 77 clinical queries. Clinical responses were achieved in 29 of 47 (62%) of patients post-HSCT including 73% of patients evaluable at 1-month post-infusion, meeting the primary efficacy endpoint (>52%). Secondary graft rejection occurred in one child following VST infusion as described in a companion article. Corticosteroids, graft-versus-host disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment correlated with poor response, while uptrending absolute lymphocyte and CD8 T cell counts correlated with good response. This study highlights key clinical factors that impact response to VSTs and demonstrates the feasibility and efficacy of this therapy in pediatric HSCT.

Для цитирования: Keller Michael D, Hanley Patrick J, Chi Yueh-Yun, Aguayo-Hiraldo Paibel, Dvorak Christopher C, Verneris Michael R, Kohn Donald B, Pai Sung-Yun, Dávila Saldaña Blachy J, Hanisch Benjamin, Quigg Troy C, Adams Roberta H, Dahlberg Ann, Chandrakasan Shanmuganathan, Hasan Hasibul, Malvar Jemily, Jensen-Wachspress Mariah A, Lazarski Christopher A, Sani Gelina, Idso John M, Lang Haili, Chansky Pamela, McCann Chase D, Tanna Jay, Abraham Allistair A, Webb Jennifer L, Shibli Abeer, Keating Amy K, Satwani Prakash, Muranski Pawel, Hall Erin, Eckrich Michael J, Shereck Evan, Miller Holly, Mamcarz Ewelina, Agarwal Rajni, De Oliveira Satiro N, Vander Lugt Mark T, Ebens Christen L, Aquino Victor M, Bednarski Jeffrey J, Chu Julia, Parikh Suhag, Whangbo Jennifer, Lionakis Michail, Zambidis Elias T, Gourdine Elizabeth, Bollard Catherine M, Pulsipher Michael A. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.. Nature communications. 2024. DOI: 10.1038/s41467-024-47057-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.